Effects of central dopaminergic stimulation by @entity3826 on speech in XXXX .

@entity1 @entity2211 @entity73 @entity409 @entity910 @entity191 @entity3826 @entity1726 @entity8408
OBJECTIVE: To determine the effect of central dopaminergic stimulation with @entity3826 on speech in @entity1726 . BACKGROUND: Most @entity1 with @entity1726 have a @entity8408 . Of those, 89% have involvement of laryngeal function, and 45% have additional @entity409 . The effect of dopaminergic medications on these two dimensions of @entity73 in @entity1726 has not been selectively studied. METHODS: In a randomized, double-blind, placebo-controlled crossover design, @entity1 with @entity1726 and @entity73 , Hoehn and Yahr stages 2 to 4 "off," and without severe @entity910 were given placebo or @entity3826 injections 0.05 mg/kg subcutaneously during two consecutive outpatient visits. They were pretreated with @entity2211 for 48 hours and were tested off their parkinsonian medications for 12 hours. Laryngeal function was assessed by maximum sustained vowel phonations and comfortable vowel phonations. Articulatory function was evaluated by speech intelligibility score, speaking rate, and efficiency ratio. RESULTS: Ten @entity1 , mean age 73.4 years (SD = 6.6), disease duration 8.7 years (SD = 6.3), were tested. The baseline motor score on the Unified @entity191 Rating Scale (UPDRSm) and all experimental speech variables were equivalent on both placebo and @entity3826 days. At a dose of @entity3826 that provoked improvement in UPDRSm (p = 0.0078), no index of either laryngeal or articulatory function improved significantly after @entity3826 administration. CONCLUSION: Laryngeal and articulatory speech components are not under prominent dopaminergic control in @entity1726 . Treatment regimens should focus on nondopaminergic pharmacology and other therapies.
